Search results
Updates from NurExone: Growth Conference Presentation and Website Relaunch
Digital Journal· 3 hours agoNurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed ...
Palestinian writers have long explored the horrors of amputation
The Conversation via Yahoo Canada News· 21 hours agoHe dies a few days later. Amputated stories After the creation of Israel in 1948, Emile Habiby, the...
Shipping Industry Rises 20% Year to Date: 3 Stocks to Buy
Zacks via Yahoo Finance Canada· 1 day agoKEX has a trailing four-quarter earnings surprise of 10.26%, on average. KEX has a market...
For Israel's Reform Jews, no need to follow US peers in ordaining rabbis in interfaith marriages
Religion News Service· 2 days agoAs president of the Reform movement’s Hebrew Union College-Jewish Institute of Religion, Andrew...
Yemen's Houthis claim attack on vital target in Israel's Haifa
Reuters via Yahoo Canada News· 3 days agoYemen's Houthis said on Tuesday that they, along with the Islamic resistance in Iraq, have conducted...
Who are directors of football and what do they do?
Premier League· 4 days agoAll these roles have come to the top of the news agenda this season in the Premier League. First there was the departure of Newcastle United’s sporting director Dan Ashworth so that he could ...
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
Digital Journal· 7 days agoNurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore ...